ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 175

The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis

Richard Conway1, Michele Doran2, Finbar (Barry) D. O'Shea3 and Gaye Cunnane2, 1Rheumatology, St James's Hospital, Dublin, Ireland, 2Dept of Rheumatology, St James's Hospital, Dublin, Ireland, 3Rheumatology Dept, St James's Hospital, Dublin, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Hepatitis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Infection-related Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Hepatitis testing is an important pre-requisite to the diagnosis and treatment of patients with rheumatic disease. Joint symptoms may be a manifestation of acute or chronic hepatitis B or C. Immunosuppressive treatment may increase viral load in patients with undiagnosed viral hepatitis. The prevalence of hepatitis varies amongst populations, but even in areas with low endemic levels, it is imperative to identify those in whom current or past infection may influence clinical outcome. The CDC recommends testing for 4 components: hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody and hepatitis C antibody. Although ACR recommendations do not specifically recommend hepatitis screening, they do advocate vaccination against hepatitis B in all patients. This study was conducted in order to identify new cases of hepatitis in a cohort of patients with RA attending a large university teaching hospital and to evaluate the extent of the hepatitis screen undertaken.

Methods:

One hundred consecutive patients, with a diagnosis of RA, were retrospectively assessed for completeness of hepatitis screening by reviewing their hospital records. A dedicated teaching session for all members of the rheumatology team was then conducted, highlighting the results of the survey and explaining the rationale for complete hepatitis screening in all patients with RA. Paper reminders were placed on all desks to alert staff to screen patients at clinic review. A prospective study of hepatitis screening of a separate cohort 100 consecutive out-patients with RA was then performed.

Results:

In the initial 100 patients, 21% were male, mean age was 65 years. 85% were taking methotrexate and 22% were on biologic treatments (18% anti-TNF agent, 4% Rituximab). Liver profile was abnormal in 20%. A complete hepatitis screen was present in only 8%, while 12% had a hepatitis B core antibody checked and 53% had a test for hepatitis C.

In the 100 patients assessed after staff education, 26% were male, mean age was 63 years. 86% were taking methotrexate and 27% were on biologic treatments (23% anti-TNF agent, 4% Rituximab). Liver profile was abnormal in 30%. A full hepatitis screen was available in 63%, while 65% had a hepatitis B core antibody checked and 81% had a test for hepatitis C.

In the total 200 patients, we identified 3 cases of positive hep B core antibody, 11 cases of positive hep B surface antibody and 1 case of positive hep C antibody. On retrospective analysis, 2 had identifiable risk factors for blood-borne infections (both healthcare workers).

Table 1: Completeness of Hepatitis Screening

 

Pre education, n=100

Post education, n=100

Any hepatitis screen

54%

81%

Full hepatitis screen

8%

63%

Hep B surface antigen

40%

77%

Hep B surface antibody

46%

77%

Hep B core antibody

12%

65%

Hep C antibody

53%

81%

Conclusion:

Even in populations where hepatitis B or C is not endemic, laboratory screening will reveal new cases of hepatitis that should be identified prior to immunosuppressive treatment. Educational initiatives are helpful in teaching staff working in busy clinical environments to screen patients, but ongoing reminders are likely to be essential.


Disclosure:

R. Conway,

Roche Pharmaceuticals,

2,

UCB Pharma,

2,

Merck Pharmaceuticals,

7;

M. Doran,
None;

F. D. O’Shea,
None;

G. Cunnane,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-hepatitis-screening-on-diagnosis-and-treatment-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology